Abstract

Salla Surya Prakasa Rao, *Dr. Sai Sekhar Pyla and Billa Susmitha

ABSTRACT

Introduction: Diabetes mellitus is now a leading cause of morbidity and mortality. SGLTR 2 inhibitors reduce proximal tubular glucose reabsorption and increases urinary glucose excretion. Dapagliflozin is selected as the drug in this study for the treatment of control of PPG in TYPE 2 DM patients to see the effect without changing the base line medication. Objectives: To observe the effect of Dapagliflozin on post prandial blood glucose in Type2 DM. Materials and Methods: APPROVAL: Prior permission was obtained from Institutional Ethical Committee before study was undertaken in the Department of Medicine of NRI Institute Of Medical Sciences, Sangivalasa, Visakhapatnam) on 100 patients admitted during January 2020 to December 2020. Inclusion Criteria: The study will include Type 2 DM patient of >15 yr age having elevated FPG/ normal FPG with increasing PPG attended to this NRIIMS during study period. Exclusion criteria (1) Pregnancy (2) Inflammatory bowel disease, IBS (3) Chronic Kidney Disease (4) Acute or chronic disease which may cause tissue hypoxia (4) Hepatic failure. Results and Conclusion: Dapagliflozin monotherapy is useful in the early stage Type2 DM with elevated post prandial plasma glucose. PPG results before and after therapy was of average 230 mg/dl and 130 mg/dl respectively after 24 wks. Patient on Biguanides when PPG is uncontrolled, adding Dapagliflozin significantly reduced PPG in patients. Before and after therapy with Dapagliflozin were on average 240 mg/dl and 156mg/dl respectively after 24 weeks. Patient on insulin therapy with increasing PPG, adding Dapagliflozin decreased PPG effectively. Before and after therapy with Dapagliflozin were 220 mg/dl and 160 mg/dl respectively after 24 weeks.